Home » Newsletters » BioWorld

BioWorld

Oct. 6, 1992

View Archived Issues

AXED PERSEPTIVE PRESIDENT AMENDS SUIT

GENENTECH RETURNS DRUG TO TELIOS

TELOR GETS 'STRESS' PROTEIN RIGHTS

FDA APPROVES EXPANDED USE FOR STAVUDINE

FETAL TISSUE ALTERNATIVES IN PARKINSON'S RESEARCH

LIFECORE STOCK PLUNGES AFTER TRIAL ANALYSIS

APPLIED BIO SPINS OFF SUBSIDIARY

BIOTECHNICA ACQUIRES SEED COMPANY

DYNAGEN COMPLETES SECONDARY

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
In the clinic for June 12, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Anixa, Beone, Bioinvent, Blossomhill, C4, Cellectis, Climb, Elixiron,...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...